The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis

✍ Scribed by Kevin M. Pantalone; Michael W. Kattan; Changhong Yu; Brian J. Wells; Susana Arrigain; Anil Jain; Ashish Atreja; Robert S. Zimmerman

• Publisher: Springer
• Year: 2009
• Tongue: English
• Weight: 286 KB
• Volume: 46
• Category: Article
• ISSN: 0940-5429
• DOI: 10.1007/s00592-008-0090-3